Atossa Genetics to Present at the 15th Annual BIO CEO and Investor Conference Presentation to Be Webcast at 1:00 pm ET on February 11, 2013 SEATTLE, WA -- (Marketwire) -- 01/28/13 -- Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company(TM), announced today that Dr. Steven C. Quay, M.D., Ph.D., FCAP, Chairman, CEO and President, will present the Company's products and services at the 15th Annual BIO CEO and Investor Conference at the Waldorf Astoria Hotel in New York City, on Monday, February 11, 2013, at 1:00 pm Eastern Time (10:00 am Pacific Time). Dr. Quay's presentation will be webcast via the Company's website at www.atossagenetics.com. Dr. Quay stated, "The national launch of our ForeCYTE Breast Health Test is an important achievement that positions Atossa for accelerated growth in 2013 and beyond. I look forward to presenting our business model, marketing plan, and additional products and laboratory services to institutional investors at this premier event. I believe the 2013 U.S. rollout of our ForeCYTE and ArgusCYTE Breast Health Test, launch of the FullCYTE Breast Health Test and NextCYTE Breast Health Test, and initiation of clinical trials for our intraductal therapy, represent significant upside potential for investors this year." About Atossa Genetics, Inc. Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company(TM), is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions. The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for p atients and their caregivers. Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks detailed from time to time in the Atossa's final prospectus, dated November 7, 2012, filed with the U.S. Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. Contact: Atossa Genetics, Inc. Steven C. Quay, M.D., Ph.D., FCAP Chairman, President and CEO of Atossa Genetics and Director of the National Reference Laboratory for Breast Health 800-351-3902 Steven.Quay@AtossaGenetics.com Matthe w D. Haines (Investors and Media) Managing Director MBS Value Partners 212-710-9686 Matt.Haines@mbsvalue.com Adam Holdsworth Dian Griesel Inc. 212-825-3210 email@example.com
Atossa Genetics to Present at the 15th Annual BIO CEO and Investor Conference
Press spacebar to pause and continue. Press esc to stop.